Table 1.
Demographic characteristics of 103 patients with inflammatory myopathies.
Fig 1.
Anti-cytosolic 5’-nucleotidase 1A (NT5c1A) antibody ELISA.
Antibodies reactive with recombinant NT5c1A protein by ELISA in sera from patients with inflammatory myopathy and valosin-containing protein (VCP)-related patients with myopathy. The cut-off level for positivity is indicated by the broken line.
Table 2.
Clinicopathologic presentation and laboratory parameters of patients with anti-NT5C1A antibody (n = 14).
Fig 2.
Pathology findings in patients with anti-NT5c1A antibody seropositive IBM: P4 (A and B) and P5 (C and D). In patient P4, pronounced muscle fiber size variation with atrophic changes and internalized nuclei, endomysial inflammatory infiltrates, and rimmed vacuoles. (A, hematoxylin and eosin [H&E] stain, B, modified Gomori trichrome [GT] stain, Magnification: x400). In patient P5, variable sizes of muscle fibers with endomysial inflammatory infiltrate without any partial muscle fiber invasion. (C, H&E stain, D, modified GT stain, Magnification: x400).
Table 3.
Clinicopathological features of 20 patients with inclusion body myositis according to anti-NT5c1A antibody status.
Fig 3.
Lower limb magnetic resonance images of four inclusion body from patients with myositis and seropositive for anti-NT5c1A antibody: P2(A-F), P6(G-L), P7(M-R), and P1 (S-X) taken 45, 55, 70, and 84 months after symptom onset, respectively.
Table 4.
Comparison of clinical features between inclusion body myositis (IBM) and non-IBM inflammatory myopathies with anti-NT5c1A antibody.